The combined activation of K(Ca)3.1 and inhibition of K(v)11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells

BACKGROUND: Platinum-based drugs such as Cisplatin are commonly employed for cancer treatment. Despite an initial therapeutic response, Cisplatin treatment often results in the development of chemoresistance. To identify novel approaches to overcome Cisplatin resistance, we tested Cisplatin in combi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Cancer
Main Authors: Pillozzi, Serena, D'Amico, Massimo, Bartoli, Gianluca, Gasparoli, Luca, Petroni, Giulia, Crociani, Olivia, Marzo, Tiziano, Guerriero, Angela, Messori, Luigi, Severi, Mirko, Udisti, Roberto, Wulff, Heike, Chandy, K George, Becchetti, Andrea, Arcangeli, Annarosa
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2018
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5785745/
https://ncbi.nlm.nih.gov/pubmed/29161243
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.392
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados